anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Safety and accuracy measures may be provided in a medicament delivery device. The medicament delivery device may be able to identify the inadvertent delivery of duplicate medicament boluses by a user. The exemplary embodiments may set limits for maximum allowable medicament bolus doses and maximum cumulative bolus doses over an interval. The exemplary embodiments may provide automatic meal detection and may use detection of meals in determining whether a user-requested medicament bolus dose should be adjusted or rejected. The exemplary embodiments may facilitate delivery of partial boluses and the delivery of remainders of the boluses contingent on acceptable glucose level trends of the user. The exemplary embodiments may resolve potential conflicts among multiple medicament delivery devices via a broker or by providing a single actor, such as a medicament delivery controller, that has sole control of dosing and delivery of medicament boluses.
Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose perampanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses \[target Breath Alcohol Concentration (BrAc) =20mg%, 60mg%, and 100mg%\] in a step-wise fashion.
OBJECTIVE: This study evaluates the feasibility of reducing in-person appointments by utilizing Remote Check (RC) in pediatric cochlear implant (CI) recipients and investigates the most suitable age range for implementing RC.
METHODS: Fifty-eight pediatric CI recipients, aged 1-17 years, were evaluated using a web-based RC application by audiologists. Most (84.5 %) used verbal communication. Inclusion criteria required stable map status, caregiver tech proficiency, and a compatible phone.
RESULTS: Remote assessments were beneficial, with 89.7 % of participants successfully completing RC. Aided threshold tests (ATT) were completed in 73.2 % of participants, while speech-in-noise tests (Digit Triplet Test, DTT) were completed in 47.3 %. Children as young as 4 successfully completed ATT, while a minimum age of 7 was required for DTT. A significant relationship between age and test success was demonstrated. Verbally communicative children had higher completion success rates. Parental education was significantly correlated with DTT success, with higher success rates in children whose parents had undergraduate degrees. With RC use, 69 % of children did not need clinic visits, emphasizing the need for personalized and remote support for optimal cochlear implant performance. In-person appointments were primarily required due to concerns about the duration of device usage.
CONCLUSION: The study confirms the effectiveness and feasibility of using RC in pediatric CI users, even as young as one year old with stable aided hearing. The findings advocate for the integration of RC into routine follow-up protocols, offering a more accessible option for enhanced patient care.
This program is self-guided, digital, and approximately 30 minutes in length. Content is designed to help adolescents improve their study skills. This program includes: (1) An introduction to study skills; (2) Testimonials from "valued others" describing their use of study skills; (3) Description of helpful and commonly used study skills (e.g., note-taking); and (4) Activities designed to encourage adolescents to practice these skills in their daily lives.
Thermosetting resins are prepared by polymerizing under the influence of 0.1-5 per cent of an alkaline catalyst, if desired with the aid of heat, products containing at least two ethylene oxide groups which are obtained by the reaction in the presence of alkali of the phenolic hydroxyl groups of a dihydric phenol with epichlorhydrin or a -dichlorhydrin, e.g. as described in Specification 518,057. Suitable dihydric phenols are resorcinol and diphenylolpropane. Suitable catalysts are alkali hydroxides, calcium oxide, sodium amide, diethylamine, dibutylamine, piperidine, piperidine benzoate, the piperidine salt of pentamethylene dithiocarbamic acid, trimethylamine, triethanolamine, the diethylamine salt of diethyldithiocarbamic acid, and also the product of combination of piperidine and benzaldehyde.  The resins may be coloured with organic or inorganic colouring matter.  Filling materials, e.g. asbestos or wood meal or plasticisers may be added to the resins.  In example 1, 1 mol. of resorcin is dissolved in 2 mols. of caustic soda, heated up to 75 DEG  C. and epichlorhydin is added drop by drop with continuous stirring.  Stirring is continued and the product cooled, washed and dehydrated on a water bath.  Piperidine is added to the first material and the mass is cooled.  A resinous product soluble in acetone and benzene is obtained.  It hardens with 1 1/2 hours heating at 100 DEG  C., becoming infusible and insoluble.  In example 2, a similar resin is prepared, employing diphenylol propane in place of resorcin and the piperidine salt of pentamethylene dithiocarbamic acid as the catalyst.  The unhardened resin is soluble in acetone, chloroform, and 1 : 4 alcohol : benzol mixture.  The products are suitable for electrical articles, billiard balls or dentures, or in solution as varnishes.  Specification 477,843 also is referred to. As open to public inspection under Sect. 91, the Specification mentions hydroquinone, dioxydiphenyl sulphone and condensation products of phenols with aliphatic, aryl aliphatic, aryl or cyclo-ketones as suitable dihydric phenols from which the ethylene oxide derivatives may be prepared.  Guanidine and its derivatives are mentioned as suitable catalysts.  This matter forms no part of the Specification as accepted.
Drug: HS-20094 administered subcutaneously (SC) once a week. Drug: Placebo administered subcutaneously (SC) once a week.
1\. Irregular bleeding. The most common side effect of POPs is a change in menstrual bleeding. Your periods may be either early or late, and you may have some spotting between periods. Taking pills late or missing pills can also result in some spotting or bleeding.

2\. Other side effects. Less common side effects include headaches, tender breasts, nausea and dizziness. Weight gain, acne and extra hair on your face and body have been reported, but are rare.

If you are concerned about any of these side effects, check with your doctor or clinic.
FIELD: immunochemicals. SUBSTANCE: secretory part of epithalamus is disintegrated, homogenized, extracted, and centrifuged. Desired product is purified and dried. Method is distinguished by performing: homogenization in physiologic solution at pH 4.8-5.0 without preliminary acetone treatment, extraction with the same solution for 1-3.5 hr at constant stirring, centrifugation at 19-20 thousands rpm for 1 hr, isolation of active material with molecular weight 300-3000 D by gel chromatography consecutively on Sephadex G-75 and G-25, and lyophilic drying of final product. EFFECT: increased yield of desired material and its specific activity, simplified procedure, and preserved environmental safety. 2 dwg, 4 tbl, 17 ex
Glioblastoma is a malignant and highly invasive tumor, which requires new approaches to search for chemotherapeutic agents. Sanggenon C (SC) mainly exists in the root bark of white mulberry. Although its anti-tumor effects have been reported in some cancers, the mechanism remains unclear. In this study, we used microscopic observation, transwell assay, and immunofluorescence assay to verify the effect of Sanggenon C on the migration and invasion of glioblastoma cells. We then carried out the gene set enrichment analysis (GESA), real-time qPCR assay and ubiquitination assay to delineate the molecule mechanism by which Sanggenon C affects the migration and invasion ability of glioblastoma. With the addition of Sanggenon C, glioblastoma cells were rounded up, with the migration and invasion ability weakened as verified by transwell assay and immunofluorescence assay. The results of GESA suggested that SC might regulate the expression of genes associated with migration and invasion and affect the activity of Wnt/β-catenin signaling pathway. Western blotting revealed that Sanggenon C promoted the ubiquitination of β-catenin to reduce the levels of β-catenin and its downstream proteins. This was further supported by the results of real-time qPCR analysis of target genes of β-catenin. Taken together, SC inhibits glioblastoma cell migration and invasion by enhancing β-catenin ubiquitination. Our work suggests a new direction for the treatment of glioblastoma.
The scar repair inevitably causes damage of skin function and loss of skin appendages such as hair follicles (HF). It is of great challenge in wound repair that how to intervene in scar formation while simultaneously remodeling HF niche and inducing in situ HF regeneration. Here, chemical reprogramming techniques are used to identify a clinically chemical cocktail (Tideglusib and Tamibarotene) that can drive fibroblasts toward dermal papilla cell (DPC) fate. Considering the advantage of biomaterials in tissue repair and their regulation in cell behavior that may contributes to cellular reprogramming, the artificial HF seeding (AHFS) hydrogel microspheres, inspired by the natural processes of "seeding and harvest", are constructed via using a combination of liposome nanoparticle drug delivery system, photoresponsive hydrogel shell, positively charged polyamide modification, microfluidic and photocrosslinking techniques. The identified chemical cocktail is as the core nucleus of AHFS. In vitro and in vivo studies show that AHFS can regulate fibroblast fate, induce fibroblast-to-DPC reprogramming by activating the PI3K/AKT pathway, finally promoting wound healing and in situ HF regeneration while inhibiting scar formation in a two-pronged translational approach. In conclusion, AHFS provides a new and effective strategy for functional repair of skin wounds.
The invention provides three polymorphic forms of crystalline levosalbutamol sulphatedesignated herein as Forms (I), (II) and (III). Crystalline levosalbutamol sulphateForm I is characterised by a powder XRD pattern with peaks at 10.8, 11.9, 13.0,18.3, 28.5 0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form(II) is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7,19.1, 27.2, 30.7 0.2 degrees 2 theta. Crystalline levosalbutamol sulphateForm (III) is characterised by a powder XRD pattern with peaks at 5.5, 6.9, 7.3,18.7 0.2 degrees 2 theta. Processes for making the new polymorphic formsand pharmaceutical compositions comprising them are also provided. A pharmaceuticalcomposition comprises a therapeutically effective isomer of salbutamol ora salt, solvate, ester, derivative or polymorph thereof, a glucocorticoid anda pharmaceutically acceptable carrier or excipient and optionally one or moreother therapeutic agents. Preferably the composition is an aerosol formulation comprisingthe drugs, a propellant and optionally one or more other ingredients, such asa surfactant, cosolvent, or bulking agent. Alternatively, DPI or inhalation suspensionsmay be used.
PURPOSE: An oral formulation containing pelubiprofen is provided to improve release rate and stability by minimizing impurity and to ensure rapid effect and bioavailability. CONSTITUTION: A pharmaceutical formulation for oral administration with improved release rate and stability contains pelubiprofen of chemical formula 1 having average particle size of 1-30 um as an active ingredient. The pharmaceutical formulation also contains excipient of lactose, calcium hydrogen phosphate, starch or polyol, binder of hydroxyl propylcellulose or polysaccharide, disintegrant of carboxymethyl cellulose calcium, low substituted hydroxypropylcellulose or starch, or lubricant of magnesium stearate or talc. The polyol is mannitol, isomalt, or xylitol. The polysaccharide is xanthan gum or carrageenan. The pharmaceutical formulation is used in the form of tablet, granule, capsule, or dry syrup.
PURPOSE:To obtain a novel physiologically active substance having hypotensive action, by cultivating a novel microorganism belonging to the genus Actinomadura. CONSTITUTION:A novel microorganism Actinomadura spiculosospora nov. sp.k-4 (FERM-P 6101) belonging to the genus Actinomadura is cultivated, to give a novel physiologically active substance. This substance has the following physical and chemical properties. Property: white fine crystal powder. Specific rotatory power: (alpha)D<20>=-83 deg.. Melting point: showing no melting point upto 300 deg.C. solubility in solvent: soluble in 0.1N aqueous solution of NaOH, slightly soluble in water, or methanol, insoluble in chloroform, or n-hexane. Color reaction: positive in Rydon Smith reaction, iodine reaction, ninhydrin reaction, and negative in Ehrlich reaction. A constituent amino acid: phenylanlanine, an unidentified substance positive in ninhydrin reaction.
The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
Fragile X syndrome (FXS) is a genetic disorder characterized by mutation in the FMR1 gene, leading to the absence or reduced levels of fragile X Messenger Ribonucleoprotein 1 (FMRP). This results in neurodevelopmental deficits, including autistic spectrum conditions. On the other hand, Fragile X-associated tremor/ataxia syndrome (FXTAS) is a distinct disorder caused by the premutation in the FMR1 gene. FXTAS is associated with elevated levels of FMR1 mRNA, leading to neurodegenerative manifestations such as tremors and ataxia.Mounting evidence suggests a link between both syndromes and mitochondrial dysfunction (MDF). In this minireview, we critically examine the intricate relationship between FXS, FXTAS, and MDF, focusing on potential therapeutic avenues to counteract or mitigate their adverse effects. Specifically, we explore the role of mitochondrial cofactors and antioxidants, with a particular emphasis on alpha-lipoic acid (ALA), carnitine (CARN) and Coenzyme Q10 (CoQ10). Findings from this review will contribute to a deeper understanding of these disorders and foster novel therapeutic strategies to enhance patient outcomes.
PCT No. PCT/KR97/00058 Sec. 371 Date Jul. 7, 1998 Sec. 102(e) Date Jul. 7, 1998 PCT Filed Apr. 3, 1997 PCT Pub. No. WO98/19687 PCT Pub. Date May 14, 1998Natural teas for taking off the effects of drink and getting rid of or curing the hangover. The teas can be prepared by using as the main raw materials extracts of leaves, stems or roots of alder and mountain ash or powders obtained by direct pulverization of leaves, stems or roots thereof, and optionally mixing the above extracts or powders with antidotal crude herb medicines including an extract of fructus ligustic fruit and an extract of radix puerariae at various mixing ratios. The effects of the teas for curing hangover are produced by taking the teas before or after drinking.
Molecular complexes for targeting a gene encoding a microsomal enzyme selective for delivery to a cell in vivo or in vitro obtaining production of the enzyme within the targeted cell are disclosed. An expressible gene encoding a desired enzyme is complexed to a conjugate of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function whithin a cell. The molecular complex is stable and soluble in physiological fluids and can be used in antisense gene therapy to selectively transfect cells in vivo to treat inherited or acquired deficiencies in cellular microsomal enzymes.
In 99 subjects of 3-18yr with newly-onset T1D, oral administration of 140IU/kg qd of cholecalciferol will be given until the serum 25(OH)D3 was maintained at the upper limit of normal range(50-80 ng/ml\[125-200 nmol/L\], ≤100 ng/ml\[≤250 nmol/L\]) for the loading peroid. And then oral administration of 70IU/kg qd of cholecalciferol for the maintenance period, meanwhile combined with intensive Insulin therapy for 12 months.
The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition.
According to grouping，patients were premeditated with injection of ciprofol 0.2-0.5mg/kg IV. If BIS is ≤ 60, Tracheal intubation was facilitated with cisatracurium 0.2mg/kg a IV and sufentanil 0.3 μ g / kg IV. if BIS is \>60, ciprofol 0.1mg/kg was titrated intravenously, with an interval of more than 1min until the BIS is ≤ 60，and intubation was performed after cisatracurium and sufentanil injected .General anesthesia was maintained with Propofol and remifentanil in both groups.
Radical cystectomy (RC) represents the gold standard treatment for invasive bladder cancer. Reductions in morbidity and mortality from this operation have occurred in recent years through refined anaesthesia, surgical techniques, and centralization of services in high volume centres. The multimodal concept of enhanced recovery after RC (ERAS), which includes pre, intra and post operative steps, has also helped to reduce the length of stay and complications after RC further.

For most abdominal surgery, it is recognized that minimally invasive surgery is less morbid than open surgery, and produces improvements in post-operative recovery without altering the curative nature of the procedure. However, to date, there is little or conflicting evidence of any benefit from minimally invasive surgery over open surgery for RC. This may reflect the complex nature of this procedure (involving surgery to both the urinary and gastro-intestinal tracts), limitations of the current evidence or that there is no benefit. To date, three prospective trials have compared RARC with open RC (ORC). However, each has been limited by sample size and design, or their application of RARC with extra-corporeal reconstruction or have yet to report.

The investigators believe that there are no studies (reported or planned) that have compared optimal RARC (e.g. with intra-corporeal reconstruction) with optimal ORC (e.g. high volume centre using ERAS). In addition, the investigators believe none have adequately assessed the rehabilitation from RC. As such, the investigators now propose a prospective RCT to randomize eligible patients to either ORC or RARC. The investigators will focus upon measures of functional recovery and the return to normal activities.
The utility model relates to a silk non-woven fabric facial mask, in particular to a non-woven fabric facial mask made of silk completely, wherein skin care essence liquid soaks through the non-woven fabric facial mask. The utility model belongs to the technical field of skin care products. The silk non-woven fabric facial mask comprises a non-woven fabric layer and a pearl membrane layer, the skin care essence liquid is used for soaking through the non-woven fabric layer, and eye holes, a nose portion cutting opening and a mouth portion cutting opening are formed in the non-woven fabric layer in sequence. Second eye holes, a second nose portion cutting opening and a second mouth portion cutting opening are formed in the pearl membrane layer in sequence. A plurality of carrier holes are formed in the pearl membrane layer. The silk non-woven fabric facial mask is simple, compact and reasonable in structure, easy to use, high-efficiency and safe. The silk non-woven fabric facial mask has natural affinity performance with skin and is capable of fully giving a full play to the skin care essence liquid.
Methadone differs from many other opioid agonists in several important ways. Methadone's pharmacokinetic properties, coupled with high interpatient variability in its absorption, metabolism, and relative analgesic potency, necessitate a cautious and highly individualized approach to prescribing. Particular vigilance is necessary during treatment initiation, during conversion from one opioid to another, and during dose titration. 

While methadone’s duration of analgesic action (typically 4 to 8 hours) in the setting of single-dose studies approximates that of morphine, methadone’s plasma elimination half-life is substantially longer than that of morphine (typically 8 to 59 hours vs. 1 to 5 hours). Methadone's peak respiratory depressant effects typically occur later, and persist longer than its peak analgesic effects. Also, with repeated dosing, methadone may be retained in the liver and then slowly released, prolonging the duration of action despite low plasma concentrations. For these reasons, steady-state plasma concentrations, and full analgesic effects, are usually not attained until 3 to 5 days of dosing. Additionally, incomplete cross-tolerance between mu-opioid agonists makes determination of dosing during opioid conversion complex. 

The complexities associated with methadone dosing can contribute to cases of iatrogenic overdose, particularly during treatment initiation and dose titration. A high degree of "opioid tolerance" does not eliminate the possibility of methadone overdose, iatrogenic or otherwise. Deaths have been reported during conversion to methadone from chronic, high-dose treatment with other opioid agonists and during initiation of methadone treatment of addiction in subjects previously abusing high doses of other agonists.